A pilot study of MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in small-cell lung cancer.

MVP chemotherapy (mitomycin C 8 mg m(-2), courses 1, 2, 4 and 6, vinblastine 6 mg m(-2), cisplatin 50 mg m(-2)) is an active low-toxicity regimen in non-small-cell lung cancer (NSCLC). Based on the single-agent activity of these agents in SCLC, we have conducted a phase II trial of MVP in SCLC. Fift...

Descripción completa

Detalles Bibliográficos
Autores principales: Hickish, T. F., Smith, I. E., Nicolson, M. C., Ashley, S., Priest, K., Spencer, L., Norman, A., Middleton, G., O'Brien, M. E.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150370/
https://www.ncbi.nlm.nih.gov/pubmed/9667676

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150370/
https://www.ncbi.nlm.nih.gov/pubmed/9667676

Ejemplares similares